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Abstract 
Background: To investigate whether atherogenic dyslipidemia, a dyslipidemic profile combining elevated triglyc-
erides and low high-density lipoprotein (HDL) cholesterol, is predictive of risk of silent myocardial ischemia (SMI) or 
angiographic coronary artery disease (CAD) in asymptomatic patients with type 2 diabetes.
Methods: Cohort study in 1080 asymptomatic patients with type 2 diabetes with a normal resting electrocardio-
gram, at least one additional cardiovascular risk factor and low density lipoprotein (LDL) cholesterol <3.35 mmol/L. 
Patients initially underwent screening for SMI by stress myocardial scintigraphy. Patients with SMI underwent coronary 
angiography.
Results: Overall, 60 (5.5 %) patients had atherogenic dyslipidemia (triglycerides ≥2.26 mmol/L and HDL cholesterol 
≤0.88 mmol/L). In multivariate analyses taking into account the parameters associated in univariate analyses with 
SMI and then CAD, atherogenic dyslipidemia was associated with SMI (odds ratio 1.8[1.0–3.3]), as were male gender 
(OR 2.1[1.5–2.9]), BMI (OR 0.97[0.94–0.997]), retinopathy (OR 1.4[1.1–1.9]), peripheral occlusive arterial disease (POAD: 
OR 2.5[1.6–3.8]) and mean blood pressure (OR 1.01[1.00–1.03]); atherogenic dyslipidemia was associated with CAD 
(OR 4.0[1.7–9.2]), as were male gender (OR 3.0[1.6–5.6]), BMI (OR 0.94[0.90–0.995]), retinopathy (OR 1.7[1.0–2.9], POAD 
(OR 4.0[2.1–7.4]) and mean blood pressure (OR 1.03[1.01–1.05]). In the subgroup of 584 patients with LDL cholesterol 
<2.6 mmol/L, atherogenic dyslipidemia was also associated with CAD (OR 3.6[1.5–9.0]).
Conclusions: Atherogenic dyslipidemia was associated with an increased risk of SMI and silent CAD in patients with 
type 2 diabetes and LDL cholesterol levels <3.35 mmol/L. Specific management of atherogenic dyslipidemia might 
help reducing the high residual burden of cardiovascular disease.
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Background
Coronary artery disease (CAD) is the main cause of death 
and morbidity in patients with type 2 diabetes. However, 
symptomatic events represent only a part of this burden, 
as asymptomatic disease is probably at least as common 
with a high prevalence of silent myocardial infarction [1] 
and silent myocardial ischemia (SMI) [2], especially in 
those with additional cardiovascular risk factors [3–5]. 
Between one- and two-thirds of the patients with SMI 
also have angiographic evidence of coronary artery dis-
ease (CAD) [3]. SMI is strongly predictive of cardio-
vascular events and poorer outcomes [3, 6] above and 
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beyond routine risk predictors [7]. There is a strong need 
for understanding the risk factors for SMI, which in turn 
might improve early diagnosis and treatment.
Intensive multifactorial intervention targeting blood 
pressure, glycemia and low-density lipoprotein (LDL) 
cholesterol remains the cornerstone of type 2 diabetes 
management, with a substantial 50  % reduction in the 
risk of cardiovascular events [8]. However, there is a need 
to identify patients with residual risk and to target new 
cardiovascular risk factors. Lipid abnormalities usually 
persist in statin-treated CAD patients with or without 
diabetes [9]. High triglycerides levels are associated with 
high cardiovascular risk [10], the presence of CAD [11] 
and a higher mortality [12, 13]. Adjustment for high-den-
sity lipoprotein (HDL) cholesterol levels tends to attenu-
ate this association [13]. Alterations in lipid transfers to 
HDL have been reported in patients with type 2 diabetes 
and CAD [14]. Further, low HDL cholesterol levels are 
associated with CAD in patients submitted to coronary 
angiography [11] as are non-HDL-to-HDL-cholesterol 
ratio [15] and triglycerides-to-HDL-cholesterol ratio [16] 
with coronary heart disease in type 2 diabetes.
Higher triglyceride and lower HDL cholesterol levels, 
considered separately only, were reported in little series 
of subjects with type 2 diabetes and SMI or silent CAD 
[17–19]. The combination of elevated triglyceride level 
and low HDL cholesterol level, commonly named athero-
genic dyslipidemia, may therefore be a contributing fac-
tor to SMI, in particular in patients with LDL cholesterol 
in the target range [20–23]. Furthermore, controlling 
atherogenic dyslipidemia in these patients might improve 
their cardiovascular prognosis [20, 24–26]. Consequently, 
we made the hypothesis that atherogenic dyslipidemia 
was associated with SMI and CAD in asymptomatic 
patients with type 2 diabetes. We also explored the asso-




The patients were consecutively recruited between 1991 
and 2011 in the diabetes clinics of Jean Verdier Hospi-
tal, Bondy and Lapeyronie Hospital, Montpellier, France. 
The data are retrospective and observational, with no 
need for either approval by an ethics committee/institu-
tional review board or patients’ written informed con-
sent. The patients’ records/information are anonymous. 
Type 2 diabetic patients were included in the cohorts if 
they were asymptomatic, did not have heart failure, and 
had a normal 12-lead resting electrocardiogram (ECG), 
and at least one additional cardiovascular risk factor 
among dyslipidemia (total cholesterol >6.5 mmol/L and/
or LDL-cholesterol >4.1 mmol/L and/or HDL-cholesterol 
<0.9  mmol/L and/or triglycerides >2.3  mmol/L and/or 
lipid lowering medication), hypertension (blood pres-
sure ≥140/90  mmHg or anti-hypertensive treatment), 
smoking, nephropathy (urinary albumin excretion rate 
>30  mg/day on at least two measurements and/or esti-
mated glomerular filtration rate <60  mL/min), family 
history of premature CAD (before the age of 60 in first-
degree relatives), peripheral occlusive arterial disease 
(POAD: stenosis measured ≥50 % by ultrasound exami-
nation). Patients with a history of valvular heart disease, 
congenital heart disease or cardiomyopathy, or symp-
tomatic CAD were excluded. In this study, we selected 
the patients with LDL cholesterol levels <3.35  mmol/L, 
which was the target range before 2000. We also selected 
a subgroup with LDL cholesterol values <2.6  mmol/L, 
with or without lipid-modifying treatment.
Methods
At baseline, clinical examination was performed and the 
presence of diabetic complications (retinopathy, nephrop-
athy, peripheral neuropathy, POAD) was assessed. 
Patients initially underwent screening for type 1 SMI by 
201thallium myocardial scintigraphy after an ECG stress 
test, a pharmacological stress test (dipyridamole injec-
tion), or both, as previously reported [3, 7, 27]. ECG stress 
test was performed when the patient was able to exercise 
on a bicycle ergometer and was expected to have an inter-
pretable exercise ECG. If the patient was unable to exer-
cise or when the ECG stress test result was indeterminate, 
a pharmacological stress test was performed. SMI was 
defined by evidence of an abnormal ECG stress test and/
or abnormal myocardial scintigraphy imaging (i.e., defects 
in at least 3 out of 17 segmental regions). The patients 
with SMI were subsequently screened for angiographic 
coronary artery disease. CAD was defined as ≥70  % 
narrowing of the luminal diameter in the left anterior 
descending artery, the circumflex artery, a well-developed 
marginal vessel or the right coronary artery or ≥50  % 
narrowing of the left main coronary artery diameter. The 
patients with SMI but who did not undergo a coronary 
angiography were not considered in analyzing the factors 
associated with CAD.
Blood samples were taken for measurement of HbA1c 
(Dimension® technology, Siemens Healthcare Diagnosis 
Inc., Newark, USA), serum total and HDL cholesterol and 
triglycerides (enzymatic colorimetry, Hitachi 912, Roche 
Diagnostics, Meylan, France), serum creatinine (colorim-
etry, Kone Optima, Thermolab System, Paris La Défense, 
France). Urine samples were collected for measurement 
of 24-h proteinuria and 24-h urinary albumin excretion 
rate (laser immunonephelometry, BN100, Dade-Behring, 
Paris, France). LDL cholesterol was calculated according 
to the Friedewald formula and glomerular filtration rate 
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was estimated using the Modification of Diet in Renal 
Disease (MDRD) Study equation. Atherogenic dyslipi-
demia was defined in accordance with the criteria used 
in the ACCORD Lipid study [20] as the combination of 
low plasma levels of HDL cholesterol (≤0.88  mmol/L 
[34  mg/dL]) and elevated triglycerides (≥2.26  mmol/L) 
[204  mg/dL]. Non HDL cholesterol was also calculated. 
Apoproteins A1 and B were measured in the population 
of Bondy center (immunoturbidimetry, COBAS 6000, 
Roche Diagnostics, Meylan, France).
Statistical analyses
We hypothesized that the presence of atherogenic dys-
lipidemia would be associated with an increased risk for 
SMI or silent CAD. This was first investigated for the 
patients with LDL cholesterol <3.35  mmol/L and then 
in the subgroup of patients with LDL cholesterol below 
the target value (<2.6 mmol/L). No data replacement pro-
cedure was used for missing data. Continuous variables 
were expressed as mean ± SD and compared by one-way 
ANOVA or the Mann–Whitney’s U test as adequate. The 
significance of differences in proportions was tested with 
the χ2 test. Logistic regression was used for multivari-
ate analyses based on models including the factors that 
were associated with silent coronary status with a p value 
≤0.10 in univariate analyses. Odds ratios with 95 % confi-
dence intervals (95 % CI) for the risk of SMI or CAD were 
reported. We calculated the Hosmer–Lemeshow χ2 sta-
tistic (HL χ2) to test the goodness of fit between expected 
and observed probabilities of an event in the different 
models. Statistical analyses were carried out using SPSS 
software (SPSS, Chicago, IL). The level of significance for 
all tests was p < 0.05.
Results
Patient characteristics
A total of 1623 patients with type 2 diabetes were screened 
for SMI. We selected 1080 patients who had LDL choles-
terol levels <3.35  mmol/L. Their baseline characteristics 
are summarized in Table  1. Overall, patients had long-
standing diabetes (mean 13.8 years), with a high a priori 
cardiovascular risk: hypertension (76.3  %), nephropathy 
(57.3 %), smoking habits (22.8 %), familial history of pre-
mature CAD (13.0  %) and POAD (11.3  %). LDL choles-
terol was 2.4 ±  0.6 mmol/L. The 543 patients who were 
not included had significantly higher HbA1c (8.9 ± 2.5 %; 
74 ±  8 mmol/mol), more dyslipidemia (72.1 %) and less 
nephropathy (30.8 %) and statin treatment (25.0 %), with 
no difference for other parameters (Table 2). Finally, 584 
patients (5.4 %) had baseline LDL cholesterol levels below 
the target value (<2.6 mmol/L).
Atherogenic dyslipidemia was diagnosed in 60 (5.6 %) 
patients with LDL <3.35  mmol/L (Table  1) and in 35 
(6.0  %) patients with LDL <2.6  mmol/L (Table  3). In 
the study population, patients with atherogenic dys-
lipidemia had significantly higher mean total cholesterol 
and triglyceride levels, lower mean HDL cholesterol 
levels, higher non HDL cholesterol and lower apopro-
tein A1 levels, but did not differ significantly for the 
other characteristics from those without atherogenic 
dyslipidemia (Table  1). In the subgroup with LDL cho-
lesterol <2.6  mmol/L, patients with atherogenic dyslipi-
demia were younger, had higher BMI, HbA1c and total 
cholesterol, a shorter diabetes duration and lower LDL 
cholesterol compared to patients without atherogenic 
dyslipidemia. They were also more likely treated by 
fibrate (Table 3).
Stress tests results
In the total cohort, SMI was identified in 292 (27  %) 
patients. Among them, 218 subsequently underwent 
a coronary angiography, and CAD was confirmed in 
91 patients (8.4  % of the total study population of 1080 
patients and 41.7 % of the patients with SMI).
In the subgroup of 584 patients with LDL <2.6 mmol/L, 
SMI was diagnosed in 155 patients (26.5  %). Coronary 
angiography was performed in 112 subjects and CAD 
was confirmed in 45 patients.
Parameters associated with silent myocardial ischemia
Table 4 shows that male gender, lower body mass index, 
retinopathy, POAD, higher mean blood pressure, smok-
ing and atherogenic dyslipidemia including lower HDL 
cholesterol level were associated with SMI. In multivari-
ate analyses taking into account all these parameters but 
HDL cholesterol, SMI was independently associated with 
atherogenic dyslipidemia (odds ratio 1.8 [95 % confidence 
interval 1.0–3.3], p < 0.05) (Table 5). In the subgroup of 
584 patients with LDL <2.6 mmol/L, SMI was no longer 
associated with atherogenic dyslipidemia (prevalence in 
patients with vs without SMI: 7.7 vs 5.4 %, p = 0.323).
Parameters associated with silent coronary artery disease
Male gender, lower body mass index, retinopathy, micro-
albuminuria, POAD, higher mean blood pressure, smok-
ing and atherogenic dyslipidemia including lower HDL 
cholesterol and higher triglyceride levels, higher non-
HDL cholesterol and apoprotein B levels were associated 
with silent CAD (Table 4). In multivariate analyses taking 
into account all these parameters but HDL cholesterol, 
triglycerides levels, non-HDL cholesterol and apoprotein 
B; silent CAD was independently associated with athero-
genic dyslipidemia (OR 4.0 [1.7–9.2], p < 0.001) (Table 5).
In patients with LDL <2.6  mmol/L, CAD was associ-
ated with male gender (OR 4.7 [1.9–11.2], p  <  0.0001), 
lower body mass index (p  <  0.01), POAD (OR 5.3 
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[2.6–10.7]), higher mean blood pressure (p < 0.05), ath-
erogenic dyslipidemia (prevalence in patients with vs 
without CAD 15.6 vs 4.8 %, OR 3.6 [1.5–9.0], p = 0.01) 
including HDL cholesterol (p < 0.01), and smoking (OR 
2.7 [1.5–5.1], p  <  0.001); with a trend for retinopathy 
(p  =  0.09) (Table  6). Multivariate analysis taking into 
account these parameters but HDL-cholesterol showed 
that atherogenic dyslipidemia was not significantly asso-
ciated (p = 0.057) with silent CAD in patients with LDL 
<2.6 mmol/L (Table 5).
Finally, the association between atherogenic dyslipi-
demia and silent CAD was only shown for patients with 
LDL cholesterol <3.35 mmol/L (Fig. 1).
Discussion
The results of this cohort study show that atherogenic 
dyslipidemia is significantly and independently associ-
ated with asymptomatic CAD in patients with type 2 
diabetes, especially those with LDL cholesterol below 
3.35 mmol/L. Figure 1 again illustrates the potential role 
of atherogenic dyslipidemia in the residual cardiovascu-
lar risk. These findings are strengthened by the size of the 
cohort and consistency with other reports for the preva-
lence of SMI in this setting [3, 7, 27].
Prevalence of atherogenic dyslipidemia
The prevalence of atherogenic dyslipidemia was lower 
than anticipated from the ACCORD Lipid study popu-
lation (17  %), which was also characterized by long-
standing diabetes and LDL cholesterol levels in the 
target range [20]. This was not unexpected. First the 
ACCORD Lipid study defined the subgroup with athero-
genic dyslipidemia using tertile analysis [20], with thresh-
olds that were different from the tertiles in our cohort: 
0.88 mmol/L in ACCORD and 1.07 mmol/L in our series 
for HDL cholesterol, and 2.26 and 1.86 mmol/L respec-
tively for triglycerides. Second, high triglycerides and 
low HDL cholesterol are biologically associated [23]. An 
Table 1 Patients’ characteristics according to the presence or absence of atherogenic dyslipidemia
Data are n (%) or mean ± SD
CAD coronary artery disease
Total
n = 1080








 Age, years 61.6 ± 9.0 61.7 ± 9.1 59.7 ± 8.2 0.09
 Gender, male/female 614/466 577/443 37/23 0.44
 Body mass index, kg/m2 30.2 ± 5.9 30.2 ± 6.0 31.1 ± 4.9 0.23
 Waist circumference, cm 104 ± 13 104 ± 13 107 ± 10 0.37
Diabetes
 Diabetes duration, years 13.8 ± 8.5 13.9 ± 8.6 11.8 ± 6.9 0.07
 HbA1c, % 8.5 ± 1.8 8.4 ± 1.8 8.6 ± 2.0 0.42
 HbA1c, mmol/mol 69 ± 6 68 ± 6 70 ± 7 0.42
 Retinopathy, % 357 (34.2) 341 (34.7) 16 (27.1) 0.24
 Nephropathy, % 406 (57.3) 383 (57.5) 23 (53.5) 0.61
 Peripheral arterial occlusive disease, % 119 (11.3) 110 (11.1) 9 (15.8) 0.27
Additional cardiovascular risk factors
 Family history of premature CAD, % 137 (13.0) 126 (12.7) 11 (19.0) 0.16
 Hypertension, % 402 (76.3) 376 (76.3) 26 (76.5) 0.98
 Lipid parameters
  Total cholesterol, mmol/L 4.5 ± 0.7 4.5 ± 0.7 4.7 ± 0.7 <0.05
  HDL cholesterol, mmol/L 1.3 ± 0.5 1.3 ± 0.5 0.8 ± 0.1 <0.0001
  Triglycerides, mmol/L 1.7 ± 1.0 1.6 ± 0.8 3.4 ± 1.1 <0.0001
  LDL cholesterol, mmol/L 2.4 ± 0.6 2.4 ± 0.6 2.4 ± 0.6 0.27
  Non HDL cholesterol, mmol/L 3.2 ± 0.7 3.1 ± 0.7 3.9 ± 0.7 <0.0001
  Apoprotein A1, g/L 1.47 ± 0.74 1.49 ± 0.28 1.10 ± 0.12 <0.0001
  Apoprotein B, g/L 0.89 ± 0.18 0.89 ± 0.18 1.10 ± 0.12 0.06
  Fibrate treatment, % 96 (9.1) 87 (8.7) 9 (15.8) 0.09
  Statin treatment, % 438 (41.4) 415 (41.5) 23 (40.4) 0.87
 Smoking, % 245 (22.8) 226 (22.3) 19 (32.2) 0.08
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analysis of the ACCORD Lipid study suggested a more 
conservative estimate of ~10  % [28]. In a population of 
subjects with diabetes from Europe and Canada treated 
by statins, the rate of patients with both LDL cholesterol 
below target value (<2.6 mmol/L) and low HDL choles-
terol plus elevated triglycerides was 6  % [29]. Thus, the 
current study provides a more accurate estimation of the 
true prevalence of this dyslipidemic profile in a real-life 
clinical setting, in which a substantial proportion of high-
risk patients with type 2 diabetes was treated with statins.
Association between atherogenic dyslipidemia and SMI
We show here for the first time an association between 
atherogenic dyslipidemia and silent CAD. This associa-
tion was found in individuals with type 2 diabetes and 
LDL cholesterol lower than 3.35 mmol/L with a border-
line significance for those with LDL cholesterol lower 
than 2.6 mmol/L. The role of atherogenic dyslipidemia on 
incident cardiovascular events is well-known [30–32] but 
to our knowledge, few studies have previously reported 
an association between atherogenic dyslipidemia and 
prevalent cardiovascular diseases, such an association 
between a high triglyceride-to-HDL cholesterol ratio 
and left ventricular geometry in children [33] and CAD 
in type 2 diabetes [16]. Atherogenic dyslipidemia has also 
been reported to be usual in Indian patients with proven 
CAD [34]. Some studies have reported an association 
between high levels of triglycerides and SMI [17, 18] and 
CAD [18]; and between low levels of HDL-cholesterol 
and CAD [19]. However, these observations were not 
analyzed according to the combination of lipid param-
eters, statin and/or fibrate treatments, or LDL choles-
terol levels. This appears to be important as our data did 
not show any association between atherogenic dyslipi-
demia and SMI in patients with LDL cholesterol above 
3.35  mmol/L (Fig.  1). Atherogenic dyslipidemia might 
therefore contribute to residual cardiovascular risk in 
type 2 diabetes. Altogether, considering atherogenic dys-
lipidemia as a marker or a risk factor for SMI and silent 
CAD should be limited to the patients with controlled 
Table 2 Characteristics of  the patients who were included (LDL cholesterol <3.35  mmol/L) or not (LDL cholesterol 
≥3.35 mmol/L) in the study







 Age, years 61.6 ± 9.0 60.3 ± 9.2 0.09
 Gender, male/female 614/466 291/252 0.21
 Body mass index, kg/m2 30.2 ± 5.9 30.3 ± 6.4 0.786
Diabetes
 Diabetes duration, years 13.8 ± 8.5 13.7 ± 3.7 0.838
 HbA1c, % 8.5 ± 1.8 8.9 ± 2.5 <0.001
 Retinopathy, % 357 (34.2) 180 (34.0) 0.94
 Nephropathy, % 406 (57.3) 181 (30.8) <0.001
 Peripheral neuropathy, % 233 (13.9) 139 (45.4) 0.71
 Peripheral arterial occlusive disease, % 119 (11.3) 56 (10.4) 0.58
 Family history of premature CAD, % 137 (13.0) 69 (13.4) 0.83
Additional cardiovascular risk factors
 Hypertension, % 402 (76.3) 235 (72.8) 0.25
 Dyslipidemia, % 244 (65.3) 246 (72.1) <0.01
 Lipid parameters
  HDL cholesterol, mmol/L 1.3 ± 0.5 1.2 ± 0.4 0.001
  Triglycerides, mmol/L 1.7 ± 1.0 1.9 ± 1.0 <0.001
  LDL cholesterol, mmol/L 2.4 ± 0.6 4.1 ± 0.7 <0.001
  Non-HDL cholesterol, mmol/L 3.2 ± 0.7 4.9 ± 0.9 <0.0001
  Apoprotein A1, g/L 1.47 ± 0.29 1.50 ± 0.30 0.506
  Apoprotein B, g/L 0.89 ± 0.18 1.31 ± 0.23 <0.0001
 Fibrate treatment, % 96 (9.1) 61 (11.8) 0.085
 Statin treatment, % 438 (41.4) 129 (25.0) <0.001
 Smoking, % 245 (22.8) 135 (25.1) 0.30
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LDL cholesterol. However, this might have therapeutic 
implications.
Therapeutic implications
Whether the identification of patients with diabetes 
and SMI may reduce their cardiovascular risk has been 
debated [6, 35–37]. However, treating atherogenic dyslip-
idemia was never considered in these studies. Based on 
our findings, we propose that targeting atherogenic dys-
lipidemia might help to reduce the residual risk of asymp-
tomatic CAD. In support, an analysis of the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) 
study showed that treatment with fenofibrate (which low-
ers triglycerides and raises HDL cholesterol) led to a 78 % 
reduction in subsequent cardiovascular events in patients 
with silent myocardial infarction (p = 0.0003) [38]. Addi-
tionally, in the Diabetes Atherosclerosis Intervention 
Study (DAIS), fenofibrate reduced progression of CAD in 
patients with type 2 diabetes, about 50 % of them having 
clinical disease [25]. A treatment with fenofibrate versus 
placebo added to statin therapy in patients with type 2 
diabetes was associated with a 30 % reduction of cardio-
vascular events in subjects with atherogenic dyslipidemia 
as defined as in our cohort [20]. Further evidence sup-
porting the clinical benefits of fibrate-based therapy in 
patients with atherogenic dyslipidemia was provided by 
a meta-analysis of five placebo-controlled studies, which 
showed that fibrate use was associated with a 35 % reduc-
tion in the risk of coronary events [39]. Long-term mor-
tality was also shown to be reduced in patients with CAD 
who were initially allocated to bezafibrate versus placebo 
and this effect was more prominent in those with triglyc-
eride levels ≥200 mg/dL [26]. In the patients with athero-
genic dyslipidemia, achieving target non-HDL cholesterol 
levels should be a key focus of cardio-vascular risk man-
agement [40]. Non-HDL cholesterol is well defined as a 
secondary target in the treatment of dyslipidemias in the 
European Atherosclerosis Society/European Society of 
Table 3 Characteristics of the patients with LDL cholesterol <2.6 mmol/L according to the presence of atherogenic dys-
lipidemia







 Age, years 61.6 ± 9.0 60.6 ± 7.4 0.001
 Gender, male/female 334/215 24/11 0.36
 Body mass index, kg/m2 30.1 ± 6.0 31.0 ± 5.0 0.001
Diabetes
 Diabetes duration, years 14.0 ± 8.4 12.0 ± 7.3 0.003
 HbA1c, % 8.4 ± 1.9 9.0 ± 2.0 0.006
 Retinopathy, % 180 (34.0) 10 (26.8) 0.51
 Nephropathy, % 212 (60.1) 16 (69.6) 0.37
 Peripheral neuropathy, % 111 (45.9) 10 (58.8) 0.30
 Peripheral arterial occlusive disease, % 59 (11.2) 6 (18.2) 0.22
 Family history of premature CAD, % 67 (12.5) 8 (23.5) 0.07
Additional cardiovascular risk factors
 Hypertension, % 207 (80.5) 13 (72.2) 0.39
 Lipid parameters
  Total cholesterol, mmol/L 4.1 ± 0.6 4.4 ± 0.7 0.013
  HDL cholesterol, mmol/L 1.4 ± 0.5 0.8 ± 0.1 0.073
  Triglycerides, mmol/L 1.5 ± 0.9 3.7 ± 1.3 0.24
  LDL cholesterol, mmol/L 2.0 ± 0.4 1.9 ± 0.4 0.003
  Non-HDL cholesterol, mmol/L 2.7 ± 0.6 3.6 ± 0.7 <0.0001
  Apoprotein A1, g/L 1.47 ± 0.29 1.13 ± 0.13 0.001
  Apoprotein B, g/L 0.79 ± 0.16 0.91 ± 0.14 0.045
Fibrate treatment, % 41 (7.6) 6 (17.6) <0.05
Statin treatment, % 279 (52.1) 15 (44.1) 0.37
Smoking, % 126 (23.1) 12 (34.2) 0.13
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Cardiology (EAS/ESC) guidelines, which set a specific 
target 0.8  mmol/L higher than the corresponding LDL 
cholesterol target value [41]. Such was the case in our 
subpopulation with silent CAD in which subjects had 
non-HDL cholesterol level 0.88 mmol/L higher than LDL 
cholesterol (Table 4). Non-HDL cholesterol, and similarly 
apoprotein B, were associated with an increased risk of 
silent CAD. Therefore, non-HDL cholesterol should be 
an additional target in this very high-risk population.
Limitations
We acknowledge a number of limitations to this study. 
These include the observational design of the study, which 
cannot show a causal relationship but only an association 
between atherogenic dyslipidemia and SMI, the inclu-
sion of inpatients and a low prevalence of atherogenic 
dyslipidemia. Mean LDL cholesterol level in our series 
was 2.4 mmol/L but the absolute number of patients with 
atherogenic dyslipidemia who had LDL cholesterol level 
strictly below the target value of 2.6  mmol/L was low. 
Furthermore, only 41 % of the patients were treated with 
statin, which is nowadays routinely prescribed in patients 
with type 2 diabetes. However, we report one of the larg-
est ever-published series of asymptomatic patients with 
type 2 diabetes, and known CAD status, although some 
patients with SMI did not undergo a coronary angiogra-
phy. Despite these limits, the results of the study suggest 
that atherogenic dyslipidemia might be a contributing 
Table 4 Patients’ characteristics according to  the presence or absence of  silent myocardial ischemia or silent coronary 
artery disease in patients with LDL <3.35 mmol/L
Data are nη or mean ± SD
CAD coronary artery disease, SMI silent myocardial ischemia, 95CI confidence interval at 95 %
a Odds ratio comparing patients with SMI to those without















 Age, years 61.6 ± 9.2 61.5 ± 8.6 0.90 61.4 ± 9.0 61.5 ± 8.7 0.93
 Gender, male/female 405/383 209/83 2.4 [1.8–3.2] <0.0001 486/423 73/18 3.5 [2.1–6.0] <0.0001
 Body mass index, kg/m2 30.6 ± 6.2 29.1 ± 5.1 <0.0001 30.5 ± 6.1 28.4 ± 4.4 <0.01
Diabetes
 Diabetes duration, years 13.8 ± 8.5 13.5 ± 8.6 0.56 13.8 ± 8.4 13.0 ± 8.5 0.39
 HbA1c, % 8.4 ± 1.8 8.5 ± 2.0 0.43 8.5 ± 1.8 8.5 ± 2.1 0.95
 HbA1c, mmol/mol 64 ± 6 65 ± 6 0.43 66 ± 6 65 ± 6 0.95
 Retinopathy, % 243 (31.9) 114 (40.4) 1.4 [1.1–1.9] 0.01 290 (33.0) 41 (46.6) 1.8 [1.1–2.8] <0.05
 Nephropathy, % 294 (57.6) 112 (56.3) 0.74 340 (56.2) 36 (56.3) 0.99
 Microalbuminuria >30 mg/
day, %
205 (30.3) 88 (35.1) 0.17 242 (30.9) 35 (43.2) 1.7 [1.1–2.7] <0.05
 Peripheral arterial occlusive 
disease, %
60 (7.9) 59 (20.6) 3.0 [2.1–4.5] <0.0001 75 (8.5) 23 (25.8) 3.8 [2.2–6.4] <0.0001
Additional cardiovascular risk factors
 Hypertension, % 248 (74.3) 154 (79.8) 0.15 331 (75.2) 60 (81.1) 0.27
  Mean blood pressure, mmHg 92 ± 11 94 ± 13 <0.01 92 ± 12 97 ± 13 <0.0001
 Atherogenic dyslipidemia, % 36 (4.6) 24 (8.2) 1.9 [1.1–3.2] <0.05 278 (61.6) 57 (75.0) 1.9 [1.1–3.2] <0.05
 Lipid parameters
  HDL cholesterol, mmol/L 1.3 ± 0.5 1.2 ± 0.4 <0.01 1.3 ± 0.5 1.1 ± 0.4 <0.0001
  Triglycerides, mmol/L 1.7 ± 1.0 1.7 ± 0.9 0.48 1.7 ± 1.0 1.9 ± 1.1 <0.01
  LDL cholesterol, mmol/L 2.4 ± 0.6 2.4 ± 0.6 0.97 2.4 ± 0.6 2.5 ± 0.6 0.34
  Non HDL cholesterol, mmol/L 3.2 ± 0.7 3.2 ± 0.7 0.637 3.2 ± 0.7 3.3 ± 0.7 0.05
  Apoprotein A1, g/L 1.47 ± 0.29 1.47 ± 0.25 0.958 1.48 ± 0.29 1.39 ± 0.22 0.195
  Apoprotein B, g/L 0.89 ± 0.19 0.92 ± 0.18 0.205 0.89 ± 0.19 1.03 ± 0.15 0.002
 Fibrate treatment, % 67 (8.7) 29 (10.2) 0.45 76 (8.5) 11 (12.2) 0.24
 Statin treatment, % 316 (40.9) 122 (42.8) 0.57 365 (41.0) 39 (43.3) 0.66
 Smoking, % 163 (20.8) 82 (28.3) 1.5 [1.1–2.0] 0.01 196 (21.7) 32 (35.2) 2.0 [1.2–3.1] <0.01
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factor to the residual burden of cardiovascular disease in 
patients with type 2 diabetes, in line with recent expert 
consensus [40].
In conclusion, the present study demonstrates that ath-
erogenic dyslipidemia is associated with increased risk of 
both SMI and silent CAD in high-risk patients with type 
2 diabetes, especially in those with LDL cholesterol lower 
than 3.35 mmol/L. A patient screening taking this factor 
into account might help with an earlier identification of 
asymptomatic CAD. Since a significant part of the resid-
ual risk is related both to atherogenic dyslipidemia and 
silent coronary disease, targeting triglycerides and HDL 
cholesterol might be considered in patients with silent 
Table 5 Parameters explaining silent myocardial ischemia 
and coronary artery disease in multivariate analyses
Odds ratio 95 % confidence 
interval
p
Silent myocardial ischemia in patients with LDL <3.35 mmol/L: H 
Lemershow: 7.35, p = 0.499
 Male gender 2.1 1.5–2.9 <0.001
 Body mass index 0.97 0.94–0.997 <0.05
 Retinopathy 1.4 1.1–1.9 <0.05
 Peripheral occlusive 
arterial disease
2.5 1.6–3.8 <0.001





Silent coronary artery disease in patients with LDL <3.35 mmol/L: H 
Lemershow: 5.30, p = 0.725
 Male gender 3.0 1.6–5.6 <0.0001
 Body mass index 0.94 0.90–0.995 <0.05
 Retinopathy 1.7 1.0–2.9 <0.05
 Microalbuminuria NS
 Peripheral occlusive 
arterial disease
4.0 2.1–7.4 <0.0001





Silent coronary artery disease in patients with LDL <2.6 mmol/L: H 
Lemershow: 12.85, p = 0.117
 Male gender 3.0 1.1–8.2 <0.05
 Body mass index 0.07
 Retinopathy 0.09
 Peripheral occlusive 
arterial disease
3.7 1.7–8.1 0.001




 Smoking 2.2 1.1–4.4 <0.05
Table 6 Characteristics of  the patients with  LDL choles-
terol <2.6  mmol/L according to  the presence of  asympto-
matic coronary artery disease









 Age, years 61.3 ± 8.9 61.1 ± 8.4 NS
 Gender, male/
female
289/207 39/6 4.7 [1.9–
11.2]
<0.0001
 Body mass index, 
kg/m2
30.5 ± 6.1 27.6 ± 3.7 <0.01
Diabetes
 Diabetes duration, 
years
14.0 ± 8.2 12.6 ± 7.5 NS
 HbA1c, % 8.4 ± 1.9 8.5 ± 1.9 NS
 Retinopathy, % 157 (32.8) 20 (45.5) 0.09
 Nephropathy, % 193 (59.9) 17 (53.1) NS
 Microalbuminuria 
>30 mg/day, %
151 (35.4) 16 (39.0) NS
  Creatinine clear-
ance, ml/min
86.6 ± 28.6 84.8 ± 26.2 NS
  Urinary albumin 
excretion rate, 
mg/day
136.3 ± 506.7 139.1 ± 228.3 NS
  Proteinuria,  
g/day, %
0.4 ± 1.0 0.3 ± 0.3 NS
 Peripheral neu-
ropathy, %
98 (44.5) 16 (53.3) NS
 Peripheral arterial 
occlusive disease, 
%
40 (8.4) 14 (32.6) 5.3 [2.6–
10.7]
<0.0001
Additional cardiovascular risk factors
 Hypertension, % 180 (79.3) 33 (82.5) NS
  Mean blood pres-
sure, mmHg
92.0 ± 11.1 96.3 ± 11.4 <0.05
 Atherogenic dys-
lipidemia, %




  HDL cholesterol, 
mmol/L
1.3 ± 0.5 1.1 ± 0.3 <0.01
  Triglycerides, 
mmol/L
1.7 ± 1.0 1.9 ± 1.3 NS
  LDL cholesterol, 
mmol/L
2.0 ± 0.4 2.0 ± 0.5 NS
  Non-HDL choles-
terol, mmol/L
2.7 ± 0.6 2.9 ± 0.7 0.224
  Apoprotein A1, 
g/L
1.46 ± 0.30 1.42 ± 0.24 0.706
  Apoprotein B, g/L 0.80 ± 0.16 0.92 ± 0.14 0.034
 Fibrate treatment, 
%
38 (7.9) 5 (11.1) NS
 Statin treatment, % 250 (51.7) 24 (53.3) NS
 Smoking, % 111 (22.6) 20 (44.4) 2.7 [1.5–
5.1]
<0.01
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CAD and such lipid disorders. However, our findings 
need to be confirmed by prospective studies conducted 
in larger series of patients with atherogenic dyslipidemia 
and with LDL cholesterol in the target range.
Abbreviations
CAD: coronary artery disease; SMI: silent myocardial ischemia; POAD: periph-
eral occlusive arterial disease.
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